PD-1 inhibitor (sintilimab) and fruquintinib plus SOX as conversion therapy for initially unresectable gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): Updated results from a single-arm, phase 2 clinical trial.

MLA

Ma, Fei, et al. “PD-1 Inhibitor (Sintilimab) and Fruquintinib plus SOX as Conversion Therapy for Initially Unresectable Gastric/Gastroesophageal Junction Adenocarcinoma (GC/GEJC): Updated Results from a Single-Arm, Phase 2 Clinical Trial.” Journal of Clinical Oncology, vol. 43, Feb. 2025, p. 406. EBSCOhost, https://doi.org/10.1200/JCO.2025.43.4_suppl.406.

APA

Ma, F., Luo, S., Zhang, B., Ma, Q., Ji, S., Zhang, Z., Zhang, Y., Yang, W., Peng, L., Guo, D., Ren, J., Zhang, Y., Su, Y., Li, J., Liu, W., Huang, J., & Yuan, W. (2025). PD-1 inhibitor (sintilimab) and fruquintinib plus SOX as conversion therapy for initially unresectable gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): Updated results from a single-arm, phase 2 clinical trial. Journal of Clinical Oncology, 43, 406. https://doi.org/10.1200/JCO.2025.43.4_suppl.406

Chicago

Ma, Fei, Suxia Luo, Bin Zhang, Qi Ma, Sheqing Ji, Zhandong Zhang, Yonglei Zhang, et al. 2025. “PD-1 Inhibitor (Sintilimab) and Fruquintinib plus SOX as Conversion Therapy for Initially Unresectable Gastric/Gastroesophageal Junction Adenocarcinoma (GC/GEJC): Updated Results from a Single-Arm, Phase 2 Clinical Trial.” Journal of Clinical Oncology 43 (February): 406. doi:10.1200/JCO.2025.43.4_suppl.406.